High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
87.26M
+102.4%
0.930
-229.11%
18.77M
-32.42%
-1.034
-19.22%
19.10M
-14.21%
-1.026
-23.42%
Estimates Revision
The market is revising Upward the revenue expectations for AnaptysBio, Inc. (ANAB) for FY2025, with the revenue forecasts being adjusted by 78.68% over the past three months. During the same period, the stock price has changed by 97.72%.
Revenue Estimates for FY2025
Revise Upward
+78.68%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-48.65%
In Past 3 Month
Stock Price
Go Up
+97.72%
In Past 3 Month
11 Analyst Rating
Wall Street analysts forecast ANAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANAB is 66.50 USD with a low forecast of 50.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 43.300
Low
50.00
Averages
66.50
High
90.00
Current: 43.300
Low
50.00
Averages
66.50
High
90.00
Barclays
Overweight
downgrade
$83 -> $70
2025-11-11
Reason
Barclays
Price Target
$83 -> $70
2025-11-11
downgrade
Overweight
Reason
Barclays lowered the firm's price target on AnaptysBio to $70 from $83 and keeps an Overweight rating on the shares. The firm says the pathogenic T-cell depletion did not translate to a benefit in ulcerative colitis. It cites the discontinuation of rosnilimab development in ulcerative colitis for the target cut.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$59 -> $52
2025-11-11
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$59 -> $52
2025-11-11
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on AnaptysBio to $52 from $59 and keeps a Buy rating on the shares after the Phase 2 rosnilimab trial in ulcerative colitis does not meet the primary endpoint. The firm removed ulcerative colitis revenues from its model.
Wedbush
David Nierengarten
Outperform -> Outperform
downgrade
$70 -> $50
2025-11-10
Reason
Wedbush
David Nierengarten
Price Target
$70 -> $50
2025-11-10
downgrade
Outperform -> Outperform
Reason
Wedbush analyst David Nierengarten lowered the firm's price target on AnaptysBio to $50 from $70 and keeps an Outperform rating on the shares.
Stifel
Buy
maintain
$55 -> $80
2025-10-29
Reason
Stifel
Price Target
$55 -> $80
2025-10-29
maintain
Buy
Reason
Stifel raised the firm's price target on AnaptysBio to $80 from $55 and keeps a Buy rating on the shares. Phase 2 induction data for rosnilimab in UC due in November to December represents "the next major catalyst" for the company and the PD-1 agonist/depleter class, says the analyst, who thinks a signal in line with standard of care first-line biologics "would represent a clear win with potential to deepen over time" and thinks shares could trade to $70-$80 in such a scenario.
Wedbush
David Nierengarten
Outperform
maintain
$45 -> $70
2025-10-15
Reason
Wedbush
David Nierengarten
Price Target
$45 -> $70
2025-10-15
maintain
Outperform
Reason
Wedbush analyst David Nierengarten raised the firm's price target on AnaptysBio to $70 from $45 and keeps an Outperform rating on the shares. The firm notes that at an R&D Day, AnaptysBio detailed clinical development plans for CD122 antagonist mAb ANB033 in celiac disease, and highlighted a possible expansion into eosinophilic esophagitis. Importantly, the CeD trial will feature two cohorts: in addition to an expected cohort evaluating protection against gluten challenge, a second cohort will recruit patients with higher VH:CD ratios to test the ability of ANB033 to heal existing mucosal damage. Topline results are expected by year-end 2026, Wedbush adds.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$38 -> $59
2025-09-30
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$38 -> $59
2025-09-30
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on AnaptysBio to $59 from $38 and keeps a Buy rating on the shares after the company announced it is planning to separate its biopharma operations and its established royalty revenue business into two separately traded public companies. The firm upped the price target after fully modeling out expected royalties and market models for Jemperli and imsidolimab.
See All Ratings
Valuation Metrics
The current forward P/E ratio for AnaptysBio Inc (ANAB.O) is -20.46, compared to its 5-year average forward P/E of -3.87. For a more detailed relative valuation and DCF analysis to assess AnaptysBio Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.87
Current PE
-20.46
Overvalued PE
2.49
Undervalued PE
-10.24
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.99
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
3.15
Undervalued EV/EBITDA
-7.12
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
29.31
Current PS
0.00
Overvalued PS
54.25
Undervalued PS
4.37
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
ANAB News & Events
Events Timeline
(ET)
2025-11-21
09:08:11
Video: Gap Surges Following Robust Comparable Sales Increase
2025-11-21
05:05:22
AnaptysBio files lawsuit against GSK's subsidiary Tesaro
2025-11-21
05:01:23
AnaptysBio unveils $100 million stock buyback initiative
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/benzinga.png)
Preview
6.0
11-24BenzingaWedbush Affirms Outperform Rating for AnaptysBio, Keeps $50 Price Target Intact
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/3a32cbb9e1ddf9ebc44c09ebc953efdfe55cdad4e52e26a3a69c39e271609390.png)
Preview
2.0
11-22CNBCMidday Stock Highlights: Notable Movements from Oracle, Bath & Body Works, Gap, and Others
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/4c392580604113b638c2f590a90955e4e4cbe6ad2079c8ed5336328f71a02e65.png)
Preview
7.0
11-21BenzingaGSK's Tesaro Files Lawsuit Against AnaptysBio, Endangering Jemperli Royalties for Cancer Treatment
Sign Up For More News
People Also Watch
FAQ
What is AnaptysBio Inc (ANAB) stock price today?
What is AnaptysBio Inc (ANAB)'s business?
What is the price predicton of ANAB Stock?
What is AnaptysBio Inc (ANAB)'s revenue for the last quarter?
What is AnaptysBio Inc (ANAB)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for AnaptysBio Inc (ANAB)'s fundamentals?
How many employees does AnaptysBio Inc (ANAB). have?